• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

News of the day

Industry news search

Recent news

To keep up to date with news from this category use our

Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results
CARY, N.C., Nov. 4 -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related...

InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
BRISBANE, Calif., November 4, 2009 -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to...

MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
SAN DIEGO, November 3, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:...

Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia...

Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...

KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients
SOUTH SAN FRANCISCO, CA (October 15, 2009) - Phase 1/2 clinical trial results with KB001, a Humaneered(TM), high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients...